A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432791/
https://www.ncbi.nlm.nih.gov/pubmed/22002018
http://dx.doi.org/10.1007/s10637-011-9753-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432791/
https://www.ncbi.nlm.nih.gov/pubmed/22002018
http://dx.doi.org/10.1007/s10637-011-9753-y

Ejemplares similares